NAUT Nautilus Biotechnology: ערך חשבונאי למניה

The price-to-book ratio per share demonstrates that the metric level is 1.03. Nautilus Biotechnology (NAUT) develops tools for proteome research, targeting the B2B R&D sector. Business success relies on system precision and the adoption of proteomics by the scientific community. An innovative AI-driven IT architecture ensures long-term customer retention and steady growth of the user base.

Energy cost optimization of Nautilus Biotechnology (NAUT) IT platforms and transparent management are strengthening the issuer's internal capital. By analyzing the book value per share, an investor can see the remaining equity after all liabilities are settled, which allows for an assessment of the real asset value per share and determines the business's fundamental resilience to market shocks.